CurrentNeighborhood Health Plan of Rhode IslandPolicy N/A

Cayston (aztreonam for inhalation) — Coverage Criteria for Cystic Fibrosis

This policy governs coverage and authorization criteria for Cayston (aztreonam for inhalation) for members with cystic fibrosis, specifying eligible indications, age limits, and duration of authorization for initial and continued therapy.

Policy Summary

PayerNeighborhood Health Plan of Rhode Island

PolicyCayston (aztreonam for inhalation) — Coverage Criteria for Cystic Fibrosis

Policy CodePolicy N/A

Change TypeMinor — no material changes

Effective DateN/A

Next Review DateN/A

Key ActionRequest prior authorization showing member is ≥2 years old with cystic fibrosis and Pseudomonas aeruginosa present or a documented history.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

12 monthsauthorization duration

>=2 yrsminimum age

P. aeruginosarequired microbiology

FDA-onlyindication stance

Coverage Criteria for Cayston (aztreonam for inhalation)

Policy Summary

PayerNeighborhood Health Plan of Rhode Island

PolicyCayston (aztreonam for inhalation) — Coverage Criteria for Cystic Fibrosis

Policy CodePolicy N/A

Change TypeMinor — no material changes

Effective DateN/A

Next Review DateN/A

Key ActionRequest prior authorization showing member is ≥2 years old with cystic fibrosis and Pseudomonas aeruginosa present or a documented history.

SourceLink

On This Page

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Covered when ALL of the following are met:

Initial Authorization for Cayston: Member has cystic fibrosis; Cayston is prescribed to improve respiratory symptoms; Pseudomonas aeruginosa is present in airway cultures OR the member has a history of Pseudomonas aeruginosa infection/colonization; member is at least 2 years of age.12 months authorization

Coverage limited to the FDA‑approved indication; other indications are considered experimental/investigational and not medically necessary.

Continuation Therapy

Covered for continuation when ALL of the following are met:

Reauthorization for Cayston: Member was previously authorized for an indication listed in this policy and is requesting reauthorization; member is experiencing benefit from therapy as evidenced by disease stability or disease improvement.12 months authorization

Reauthorization may be granted for 12 months when benefit is demonstrated.

Use of Cayston (aztreonam for inhalation) for indications other than cystic fibrosis with Pseudomonas aeruginosa is excluded. Such uses are considered experimental/investigational and will not be covered.

Any indication for Cayston that is not FDA‑approved is considered not medically necessary and is therefore not covered under this policy.

Coding and Authorization Details

Referenced sources (no billing codes listed)mixed

No codes listed

Authorization duration

Authorization duration12 months

ReauthorizationMay be granted for 12 months when member demonstrates benefit (disease stability or improvement)

Applies toInitial and continuation authorizations for eligible members with cystic fibrosis

Minimum age

Minimum age>= 2 years

Applies toMembers with cystic fibrosis being considered for Cayston therapy

Documentation requirementClinical documentation must show member is at least 2 years old

Provider Requirements and Prior Authorization

Prior Authorization

Prior Authorization Required

Prior authorization is required for Cayston (aztreonam) and may be granted for up to 12 months for eligible members. Submit requests through the payer's prior authorization system with supporting clinical documentation. Requests for non‑FDA indications are considered experimental/investigational and will be denied.

Authorization duration: up to 12 months for eligible members
Non‑FDA indications: experimental/investigational — not medically necessary

Note

Provider Action — submit complete documentation

Providers must take the following actions when requesting authorization: verify member age, confirm presence or history of Pseudomonas aeruginosa, document prior response if requesting continuation, and include all requested records to avoid delays or denial.

Source chunk indices: 0
Source chunk indices: 2
Source chunk indices: 3

Documentation Required

Required Clinical Documentation

Clinical documentation must include age (member must be ≥ 2 years), evidence of Pseudomonas aeruginosa in airway cultures OR documented history of Pseudomonas aeruginosa infection/colonization, and for continuation requests, evidence of clinical benefit (disease stability or improvement).

Age requirement: ≥ 2 years
Microbiology: Pseudomonas aeruginosa present in airway cultures OR documented history of infection/colonization
Continuation: documentation of clinical benefit (disease stability or improvement)

Denial Risk

Non‑FDA Indications

Requests for Cayston for indications other than cystic fibrosis with Pseudomonas aeruginosa are considered experimental/investigational and will be denied.

All non‑CF indications: not medically necessary

Background

Cayston (aztreonam for inhalation) is FDA‑approved to improve respiratory symptoms in patients with cystic fibrosis who have Pseudomonas aeruginosa present. Coverage under this policy is limited to that FDA‑approved indication.

Definitions

Pseudomonas aeruginosa presence/history

DefinitionEither positive airway cultures for Pseudomonas aeruginosa or a documented history of Pseudomonas aeruginosa infection or colonization of the airways.

Evidence acceptedPositive airway culture results or documented clinical history in the medical record

Policy useRequired to meet coverage criteria for Cayston in cystic fibrosis patients